• This capital increase will be carried out by way of a public offer with elimination of preferential subscription rights
• The initial amount of the capital increase may be increased up to €17.25 million in the event of full exercise of the extension clause and up to €19.8 million in the event of full exercise of the extension clause and over-allotment option
• Extension of CARMAT’s financial horizon until the beginning of May 2024, in the event of completion of the initial capital increase (excluding extension clause and over-allotment option)
• After the Offer, the Company’s financing requirement over 12 months will be €37 to €55 million.
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart in the world, aiming to offer a therapeutic alternative to patients suffering from advanced biventricular heart failure (the “Company” or “CARMAT”) , announces the launch of a capital increase by way of public offering, with elimination of preferential subscription rights, for an initial amount of €15 million, which can be increased to a maximum amount of €19.8 million in case of full exercise of the extension clause and the over-allotment option.
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.